Advances in Traditional Medicine

  • 제2권2호
  • /
  • Pages.94-100
  • /
  • 2002
  • /
  • 2662-4052(pISSN)
  • /
  • 2662-4060(eISSN)
경희대학교 융합한의과학연구소 (Kyung Hee Oriental Medicine Research Center)
권호 표지
DOI QR코드

DOI QR Code

Antifibrotic effects of oriental herbs GLM001 on liver cirrhosis induced by bile duct ligation

  • Jeong, Bong-Ho (Department of Chemistry, Natural Science College, Wonkwang University) ;
  • Kim, Hee-Seok (Department of Chemistry, Natural Science College, Wonkwang University) ;
  • Kim, Chul (Department of Chemistry, Natural Science College, Wonkwang University) ;
  • Kim, Jae-Sung (Department of Chemistry, Natural Science College, Wonkwang University) ;
  • Bae, Heung-Mo (Department of Chemistry, Natural Science College, Wonkwang University) ;
  • Kwon, In-Sook (Faculty of life science, Hanil University & Presbyterian Theological Sminary) ;
  • Lee, Cheol-Han (Biotechnology Institute, Mi-Rae foundation for Biomedical Research) ;
  • JeKal, Seung-Ju (Department of Clinical Laboratory Science, Wonkwang Health Science College) ;
  • Yu, Byung-Su (Department of Chemistry, Natural Science College, Wonkwang University)
  • 발행 : 2002.08.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Liver cirrhosis is characterized by hyperaccumulation of fibrous tissue components and is commonly observed in latter or terminal states of chronic hepatic diseases. In this study, the antifibrotic effects of GLM001 on liver cirrhosis were examined in bile duct ligated rats and patients with hepatic diseases. GLM001 (250 mg/kg rat weight/ day) was administrated to cirrhotic rats for 4 weeks and to humans for 14 weeks. Bile duct ligated rats significantly increased liver collagen content and biochemical markers of hepatic injury. Liver histology showed collagen fiber deposition was increased and the normal architecture was lost with large zones of necrosis being observed frequently. GLM001 administrated rats showed significantly decreased liver collagen content, and accumulation of collagen fiber in histological analysis. Patients, who were treated with GLM001, showed decreases in biochemical markers of hepatic diseases. These results demonstrate the usefulness of GLM001 as an antifibrotic agent for liver cirrhosis.

키워드

참고문헌

  1. Ballardini G, Faccani A, Bianchi FB, Fallani M, Patrono D, Capelli M, Pisi E. (1984) Steroid treatment lowers hepatic fibroplasia, as explored by serum aminoterminal procollagen III peptide in chronic liver disease. Liver 4, 348-352.
  2. Batta AK, Saken G, Arora R, Sheffer S. (1998) Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatol. 10, 414-419. https://doi.org/10.1002/hep.1840100404
  3. Beukers R, Schalm SW. (1992) Immunosuppressive therapy for primary biliary cirrhosis. J. Hepatol. 14, 1-6. https://doi.org/10.1016/0168-8278(92)90123-7
  4. Bickel M, Baringhaus KH, Gerl M, Kanta J, Schmidts L, Stapf M, Tschank G, Weidmann K, Werneer U. (1998) Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor. Hepatol. 28, 404-411. https://doi.org/10.1002/hep.510280217
  5. Bissell DM, Maher JJ. (1996) Hepatic fibrosis and cirrhosis. Hepatology Philadelphia: Saunders, 506-525.
  6. Leveille CR, Arias IM. (1967) Pathophysiology and pharmacologic modulation of hepatic fibrosis. J. Vet. Int. Med. 7, 73-84. https://doi.org/10.1111/j.1939-1676.1993.tb03173.x
  7. Dickson ER, Flemming TR, Wiesner RH, Baldus WP. (1985) Trial of penicillamine in advanced primary biliary cirrhosis. N. Engl. J. Med. 312, 1011-1015. https://doi.org/10.1056/NEJM198504183121602
  8. Fort J, Pilette C, Veal N, Oberti F, Gallois Y, Douay O, Rosenbaum J Cales P. (1998) Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J. Hepatol. 29, 263-270. https://doi.org/10.1016/S0168-8278(98)80012-3
  9. Friedman SL. (1993) The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N. Engl. J. Med. 328, 1828-1835. https://doi.org/10.1056/NEJM199306243282508
  10. Vassalli JD, Sappino AP, Bellin D. (1991) The plasminogen activator/plasmin system. J. Clin. Invest. 88, 1067-1072. https://doi.org/10.1172/JCI115405
  11. Vassalli JD, Popper MS. (1994) Membrane proteases in focus. Nature(London) 370, 14-15. https://doi.org/10.1038/370014a0
  12. Kountaras J, Barbara H, Billing JS, Billing P. (1984) Prolonged gile duct obstruction: a new experimental model for cirrhosis in the rat. Br. J. Exp. Pathol. 65, 305-311.
  13. Jamall IS, Finelli VN. (1981) A single method to determine nanogram levels of 4- hydroxyproline in biological tissue. Anal. Biochem. 112, 70-75. https://doi.org/10.1016/0003-2697(81)90261-X
  14. Kim SN, Kim SY, Yim HK, Lee WY, Ham KS, Kim SK, Yoon MY, Kim YC. (1999) Effect of dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarbox-ylate (DDB) on chemical-induced liver injury. Biol. Pharm. Bull. 22, 93-95. https://doi.org/10.1248/bpb.22.93
  15. Kountouras J, Billing BH, Scheuer PJ. (1984) Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. J. Exp. Pathol. 65, 305-311.
  16. Rodriguez-Fragoso L, Gonzalez MP, Muriel P. (1995) Interferon-2b increase fibrolysis in fibrotic livers from bile duct ligated rats. Possible participation of the plasminogen activator. Pharmacology 51, 341-346. https://doi.org/10.1159/000139345
  17. Maher JJ, Mcguire RF. (1990) Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endotherial cells during hepatic fibrosis in vivo. J. Clin. Invest. 86, 1641-1648. https://doi.org/10.1172/JCI114886
  18. Muriel P, Suarez OR, Gonzalez P, Zuniga L. (1994) Protective effect of S-adenosyl-L-methionie on liver damage induced by biliary obstruction in rats. J. Hepatol. 21, 95-102. https://doi.org/10.1016/S0168-8278(94)80143-6
  19. Nan JX, Park FJ, Kim HJ, Ko G, Sohn DH. (2000) Antifibrotic effects of the methanol extract of Polygonum aviculare in fibrotic rats induced by bile duct ligation and scission. Biol. Pharm. Bull. 23, 240-243. https://doi.org/10.1248/bpb.23.240
  20. Neubauer J, Cristensen E, Portmann B, Caballeri J, Rodes J, Ranek L. (1985) Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis. Gut 26, 114-119. https://doi.org/10.1136/gut.26.2.114
  21. Peterson TC, Neumeister M. (1996) Effect of pentoxifylline in rat and swine models of hepatic fibrosis: role of fibroproliferation in rat mechanism. Immunopharmacol. 31, 183-193. https://doi.org/10.1016/0162-3109(95)00048-8
  22. Rockey DC, Maher JJ, Jarnagin WR, Gabbiani G, Friedman SL. (1992) Inhibition of rat hepatic limpocyte activation in culture by interferon-gamma. Hepatol. 16, 776-784. https://doi.org/10.1002/hep.1840160325
  23. Rodriguez L, Cerbon AJ, Munoz ML. (1998) Effects of colchine and colchiceine in a biochemical model of liver injury and fibrosis. Arch. Med. Res. 29, 109-116.
  24. Friedman SL, Bissel M. (1990) Hepatic fibrosis: new insight into pathogenesis. Hosp. Pract. 15, 43-51.
  25. Schuppan D. (1995) Chronische Hepatitis-Antifibrotische Therapieausaetze Z. Allg. Med. 71, 11531-11542.
  26. Schuppan D. (1990) Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteuns. Semin Liver Dis. 19, 1-10.
  27. Shimizu I, Mizobuchi Y, Yasuda M, Ma YR, Horie T, Liu F, Ito S. (1999) Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro. Gut 44, 127-136. https://doi.org/10.1136/gut.44.1.127
  28. Wiesner RM, Dickson ER, Lindor D, Jorgensen R, LaRusso NF, Baldus W. (1987) A controlled clinical trial evaluating cyclosporin in the treatment of primary biliary cirrhosis: A preliminary report. Hepatol. 7, 1025 (Abstr).
  29. Yasuda H, Imai E, Shiota A, Fujise N, Morinaga T, Higashio K. (1996) Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatol. 24, 636-642. https://doi.org/10.1002/hep.510240328